December 12, 2022
Video
Michael L. Krychman, MD, and Jack D. Sobel, MD, discuss the importance of awareness and education about RVVC, particularly given the impact of symptoms on patients’ psychosocial and sexual behavior.
December 12, 2022
Video
Michael L. Krychman, MD, and Jack D. Sobel, MD, discuss the practical challenges of access to newer, FDA-approved medications for RVVC and how the third-party reimbursement landscape may take shape in coming years.
December 12, 2022
Video
Experts explore the availability and cost as well as other unanswered questions regarding emerging agents for the treatment of RVVC.
December 05, 2022
Video
Michael L. Krychman, MD, and Jack D. Sobel, MD, review the mechanisms of ibrexafungerp and how it might fit in the treatment spectrum for RVVC.
December 05, 2022
Video
Michael L. Krychman, MD, and Jack D. Sobel, MD, review the clinical implications of the recent approval of oteseconazole, which has been shown to be efficacious and well tolerated in RVVC treatment.
November 28, 2022
Video
Thought leaders discuss the history of RVVC treatment, including the use of unapproved topical antifungals and the shortcomings of fluconazole.